Ronnie Isaacson
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,034, more than ten times the $38 reported in 2021.
Across 178 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$582
- Johnson & Johnson$340
- Otsuka America Pharmaceutical, Inc.$305
- Neurocrine Biosciences, Inc.$290
- Takeda Pharmaceuticals U.S.A., Inc.$213
- Lundbeck LLC$201
- plus $1K from 13 others
What the payments were for
- Food & beverage$2,984100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $582 |
| Johnson & Johnson | 17 | $340 |
| Otsuka America Pharmaceutical, Inc. | 17 | $305 |
| Neurocrine Biosciences, Inc. | 13 | $290 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $213 |
| Lundbeck LLC | 11 | $201 |
| Teva Pharmaceuticals USA, Inc. | 10 | $183 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $138 |
| Axsome Therapeutics, Inc. | 7 | $134 |
| Corium, LLC | 7 | $131 |
| Alkermes, Inc. | 5 | $93 |
| Vanda Pharmaceuticals Inc. | 4 | $89 |
| Tris Pharma Inc | 3 | $65 |
| Biogen | 3 | $53 |
| Ironshore Pharmaceuticals Inc. | 2 | $44 |
| Idorsia Pharmaceuticals US Inc | 3 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Indivior Inc. | 1 | $18 |
How this compares
$2,984 in reported general payments places this provider in the 85th percentile of 265 medical providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $765 |
| Guanfacine Hcl | 14 | $744 |
| Duloxetine Hcl | 21 | $728 |
| Bupropion XlBupropion Hcl | 35 | $653 |
| Lurasidone Hcl | 33 | $607 |
| Clonazepam | 31 | $508 |
| Escitalopram Oxalate | 25 | $452 |
| Lamotrigine | 56 | $449 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $278 |
| Sertraline Hcl | 24 | $270 |
| Fluoxetine Hcl | 26 | $268 |
| Alprazolam | 49 | $217 |
| Quetiapine Fumarate | 17 | $178 |
| Buspirone Hcl | 12 | $157 |
| Gabapentin | 12 | $132 |
Paid to pharmacies, not to this prescriber.
Other medical in Boise
- Jessica BishopBoise$60K
- Cali BradberryBoise$9K
- Sharene WatsenBoise$7K
- Zana DelicBoise$4K
- Jacob TebbsBoise$3K
- Scott AstleyBoise$3K
- Shawna BeechinorBoise$2K
- Melissa KroonBoise$2K
- Dillon SmithBoise$2K
- Jessie ZimmermanBoise$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.